Chargement des cours...
Prévisions
| Acheter |
1 |
| Conserver |
0 |
| Vendre |
0 |
Actualités Accéder au fil d'actualités
Dominari Holdings changes terms for Series A warrants and offers reduced exercise price
Dominari Holdings agreed incentive arrangements with holders of Series A warrants and is offering two options: exercise all warrants by September 11, 2026 at a reduced price of $2.20 per share, or exchange unexercised warrants for common shares at a ratio of 1 share for every 5 underlying warrants. If holders choose option A, the company expects gross proceeds of about $2.9 million; under option B approximately 115,000 exchange shares would be issued. After the transactions, about 1.2 million Series A warrants would likely remain outstanding; the potential shares are registered for resale in an effective registration statement, while exchange shares are subject to an exemption. » Plus sur de.investing.com
Dominari Holdings: stock rose by around 400% in 2025, strong capital-markets activity
Dominari Holdings recorded a price gain of about 400% in 2025 (from roughly $1.00 to almost $5.00) and is currently trading at approximately $4.19. The company paid dividends of around $22.2 million in 2025, generated revenue of $99.59 million (+691% YoY) and shows a very low P/E ratio of 0.46 and a price‑to‑book of 0.32. Dominari Securities completed numerous transactions, raised nearly $2 billion in capital (including leading roles in issuances) and strengthened liquidity with a current ratio of 4.74, indicating robust financial metrics and further upside potential. » Plus sur de.investing.com
Dominari Holdings announces $10 million special dividend
Dominari Holdings will pay a cash special dividend of about $10 million (approximately $0.44 per share), payable around January 23, 2026 to shareholders of record at the close of trading on December 31, 2025. The micro‑cap company, with a market capitalization of roughly $67 million, is unusually issuing a special dividend for the first time despite the stock’s strong rise in 2025. Dominari reports a solid liquidity position (current ratio 4.74) and held about $176.2 million in cash and marketable securities as of September 30, 2025; a previously filed $2 billion shelf registration was withdrawn. Tim Ledwick was also appointed CFO, and the company is pursuing growth opportunities in areas such as AI and data centers. » Plus sur de.investing.com
Dividendes historiques Dividendes
Tous les indicateurs de dividendes Tous les indicateursDonnées financières de l'entreprise
| (EUR) | juin 2026 | |
|---|---|---|
| Chiffre d'affaires | 14,71 M | 49,15 % |
| Bénéfice brut | 2,24 M | 92,27 % |
| Bénéfice net | -4,36 M | 130,96 % |
| EBITDA | -2,05 M | 87,45 % |
Données fondamentales
| Indicateur | Valeur |
|---|---|
Capitalisation boursière | 48,91 M € |
Nombre d'actions | 22,61 M |
Plus haut/bas sur 52 semaines | 7,25 € - 1,89 € |
Rendement du dividende | 55,82 % |
Dividendes TTM | 1,19 € |
Bêta | 0,87 |
Ratio P/E | -0,72 |
Ratio PEG | 0,00 |
Ratio P/B | 2,61 |
Ratio P/S | 0,42 |
Profil de l'entreprise
Dominari Holdings Inc. ist ein Biotechnologieunternehmen, das sich auf die Entwicklung niedermolekularer Krebstherapeutika konzentriert. Die Pipeline des Unternehmens umfasst Therapien für Prostatakrebs, Bauchspeicheldrüsenkrebs, akute myeloische Leukämie (AML) und akute lymphoblastische Leukämie. Das Unternehmen entwickelt DHA-dFdC, einen Wirkstoffkandidaten für die Bauchspeicheldrüse, und KPC34, ein kleines Molekül zur Behandlung von akuter myeloischer Leukämie und akuter lymphatischer Leukämie. Das Unternehmen entwickelt auch eine antivirale Plattform, die die Replikation von Viren hemmt, darunter Influenzavirus, Ebolavirus und Marburg-Virus, SARS-CoV, MERS-CoV und SARS-CoV-2. Das Unternehmen hat Lizenzvereinbarungen mit der University of Texas, der University of Maryland Baltimore, Silo Pharma Inc. und der Wake Forest University Health Sciences. Das Unternehmen war früher als AIkido Pharma Inc. bekannt und änderte im Dezember 2022 seinen Namen in Dominari Holdings Inc. um. Dominari Holdings Inc. wurde 1967 gegründet und hat seinen Hauptsitz in New York, New York.
| Nom | Dominari Holdings |
| PDG | Anthony C. Hayes |
| Siège social | New York City,
ny États-Unis |
| Site web | |
| Secteur | Finance |
| Industrie | Services financiers |
| Introduction en bourse | 18/03/1980 |
| Employés | 36 |
Symboles boursiers
| Bourse | Symbole |
|---|---|
NASDAQ | DOMH |
Frankfurt | BP2A.F |
Düsseldorf | BP2A.DU |
Découvrir des actifs
Les actionnaires de Dominari Holdings investissent également dans les actifs suivants





